FMR LLC and Abigail P. Johnson filed Amendment No. 6 to their Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of Veracyte Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 6,172,996.40 shares of Veracyte Inc. common stock.
  • Percent of class: The aggregate amount represents 7.7% of Veracyte Inc.'s outstanding common stock, according to the filing.
  • Sole voting power (FMR LLC): FMR LLC reported sole voting power over 6,170,945.50 shares, with no shared voting power.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson reported sole dispositive power over 6,172,996.40 shares, with no shared dispositive power.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Filing classification: FMR LLC is classified as a parent holding company (HC); Abigail P. Johnson is classified as an individual (IN).

FMR LLC and Johnson Disclose Veracyte Ownership as of September 30, 2026

FMR LLC, a Delaware-organized entity headquartered at 245 Summer Street, Boston, Massachusetts, filed Amendment No. 6 to Schedule 13G disclosing its beneficial ownership position in Veracyte Inc. (NASDAQ:VCYT) common stock (CUSIP 92337F107). According to the filing, the event triggering the amendment occurred on September 30, 2026, and the statement was signed on November 4, 2026.

The filing reports that FMR LLC beneficially owns 6,172,996.40 shares in aggregate, representing 7.7% of the class. FMR LLC holds sole voting power over 6,170,945.50 shares and sole dispositive power over 6,172,996.40 shares. No shared voting or dispositive power is reported. Abigail P. Johnson is listed as a separate reporting person, also attributed with 6,172,996.40 shares and 7.7% of the class, with sole dispositive power over the same amount and zero voting power reported individually.

The filing states under Item 6 that "one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VERACYTE INC," but that "no one other person's interest in the COMMON STOCK of VERACYTE INC is more than five percent of the total outstanding COMMON STOCK." The filing further certifies that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Subsidiary identification is addressed in Exhibit 99, referenced but not reproduced in the main filing text.

What Was Disclosed

FMR LLC and Abigail P. Johnson submitted Amendment No. 6 to Schedule 13G, reporting combined beneficial ownership of 6,172,996.40 shares, or 7.7%, of Veracyte Inc. common stock as of September 30, 2026, with no shared voting or dispositive power.